ASCO 2026 highlighted a shift that has been building over several years. Oncology is increasingly shaped by the convergence of multiple approaches.
If there is one practical tip for the American Society of Clinical Oncology (ASCO) Annual Meeting, it’s comfortable shoes. The scale of the congress, and the number of conversations waiting to happen, means you quickly rack up the steps.
But beyond the miles covered, what stood out this year was how oncology is evolving. Progress is no longer driven by single breakthroughs, but by the convergence of multiple approaches and increasingly personalised care. Immunotherapy still dominates, but the focus has clearly shifted toward rational combinations, earlier-line use, and integration with other modalities such as antibody–drug conjugates (ADCs), cell therapies, and even therapeutic vaccines.
This year’s plenary sessions reflected this shift, with genuinely practice-changing data: a RAS-targeted therapy in pancreatic cancer nearly doubled overall survival versus chemotherapy, marking one of the first real successes against a historically “undruggable” target, while genomic risk stratification in early breast cancer showed that around two-thirds of patients could safely avoid chemotherapy altogether.
Elsewhere, perioperative and adjuvant strategies continue to move the bar earlier in disease—for example, RET-targeted therapy dramatically reducing recurrence risk in lung cancer and intensified perioperative androgen blockade improving outcomes in prostate cancer. Alongside these headline data, there was a strong undercurrent of innovation in next-generation modalities—ADCs, bispecifics and cell therapies all continuing to push into earlier lines and broader tumour types, reinforcing the shift toward more personalised, biology-driven care.
What this means for medical communications
From a medical communications perspective, the implications are immediate and more complex than ever. Multiple mechanisms are now competing for similar patient populations, creating a crowded, competitive and rapidly evolving environment. We see this with our clients regularly, where we have to shift the focus from proof of efficacy to clarity of positioning. This requires for example, sharper biomarker strategies, more sophisticated trial designs, and stronger medical communication to articulate where and why one approach could benefit use over another.
What felt most striking at ASCO was how much the role has shifted from simple “data dissemination” to true “data translation”: helping clinicians interpret where a KRAS inhibitor fits versus an immunotherapy combination, or how to sequence ADCs in an evolving treatment pathway.
There is also a growing need to communicate nuance; de-escalation data, biomarker-driven decision-making, and tolerability trade-offs are increasingly as important as efficacy. To communication effectively, the strategy has to move well beyond broad “awareness” and toward precision positioning. Agencies need to help clients define a clearly differentiated scientific narrative, one that explains not just what the asset does, but where it fits in the treatment pathway, which patients are most likely to benefit, and why it matters versus other available or emerging options.
Beyond the science, the congress highlighted the importance of humanising innovation and the science behind it. Patient-centric storytelling and experience-led engagement are becoming increasingly important alongside the clinical data. For med comms teams, this means building integrated approaches that simplify complexity, differentiate mechanisms in crowded spaces, and connect cutting-edge data to real-world clinical decisions.
Ultimately, at ASCO this year, the real value sat not just in the data itself, but in how clearly it could be understood and applied. As the science becomes more complex, the ability to turn evidence into insight will become increasingly important.
If you’d like to discuss how these shifts could shape your communications strategy, explore our medical communications services or get in touch with the Bioscript team.
Get in touch
